New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
09:09 EDTCERUCerulean announces CRLX101 combination data presented at ASCO
Cerulean Pharma announced that three abstracts on its lead candidate, CRLX101, were included in the 2014 American Society of Clinical Oncology Annual Meeting held in Chicago. An interim analysis of CRLX101 in combination with Avastin in a Phase 1b/2 clinical trial in patients with relapsed renal cell carcinoma, which was previously presented by Stephen Keefe, of the University of Pennsylvania Abramson Cancer Center at the ASCO Genitourinary Cancers Symposium in January, also was included in the ASCO Annual Meeting's electronic compendium of abstracts. This ongoing trial has shown that CRLX101 can be combined safely with Avastin, and preliminary outcomes suggest a clinical benefit in response rate and progression-free survival. The trial is being conducted at the Abramson Cancer Center and Thomas Jefferson University Hospital. The company said, "Collectively, these abstracts demonstrate the potential value of CRLX101 in combination with other cancer treatments across a range of cancers. We're working to advance CRLX101 in combination with other cancer treatments in all three indications, and we expect to launch a randomized trial in relapsed RCC this summer."
News For CERU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2015
07:03 EDTCERUCerulean, AstraZeneca partner to evaluate LYNPARZA, CRLX101 combo
Cerulean (CERU) announced that it has entered into a collaboration with AstraZeneca (AZN) and the National Cancer Institute, part of the National Institutes of Health, to study LYNPARZA and CRLX101. The collaboration will explore the synergistic effects of AstraZeneca's LYNPARZA, a poly ADP ribose polymerase inhibitor, and CRLX101, Cerulean's inhibitor of topoisomerase 1. The NCI will conduct a combination Phase I/IIa trial in the Branch led by Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch.
November 16, 2015
16:58 EDTCERUCerulean provides update on expected clinical data publication
Subscribe for More Information
16:54 EDTCERUCerulean reports Q3 EPS (39c), consensus (41c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use